Research Analysts Set Expectations for Minerva Neurosciences Inc’s FY2019 Earnings (NERV)

Share on StockTwits

Minerva Neurosciences Inc (NASDAQ:NERV) – Equities research analysts at Jefferies Financial Group issued their FY2019 earnings estimates for Minerva Neurosciences in a report issued on Tuesday, March 12th. Jefferies Financial Group analyst B. Amin anticipates that the biopharmaceutical company will post earnings of ($1.40) per share for the year. Jefferies Financial Group also issued estimates for Minerva Neurosciences’ FY2020 earnings at ($1.77) EPS, FY2021 earnings at ($1.50) EPS and FY2022 earnings at ($0.15) EPS.

Several other equities research analysts have also recently commented on NERV. ValuEngine cut shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. BidaskClub cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. Finally, Zacks Investment Research cut shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Friday, January 4th.

NASDAQ:NERV opened at $8.25 on Friday. Minerva Neurosciences has a 12 month low of $5.80 and a 12 month high of $12.95. The stock has a market capitalization of $315.25 million, a PE ratio of -6.40 and a beta of 1.47.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.01).

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Minerva Neurosciences by 0.4% in the 4th quarter. BlackRock Inc. now owns 2,456,902 shares of the biopharmaceutical company’s stock worth $16,559,000 after acquiring an additional 8,576 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Minerva Neurosciences by 1.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,602,098 shares of the biopharmaceutical company’s stock valued at $10,798,000 after purchasing an additional 29,480 shares in the last quarter. Vanguard Group Inc. increased its stake in Minerva Neurosciences by 1.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,537,590 shares of the biopharmaceutical company’s stock valued at $19,297,000 after purchasing an additional 16,956 shares in the last quarter. Vanguard Group Inc increased its stake in Minerva Neurosciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 1,537,590 shares of the biopharmaceutical company’s stock valued at $19,297,000 after purchasing an additional 16,956 shares in the last quarter. Finally, Millennium Management LLC increased its stake in Minerva Neurosciences by 5.9% during the 4th quarter. Millennium Management LLC now owns 1,251,680 shares of the biopharmaceutical company’s stock valued at $8,436,000 after purchasing an additional 69,859 shares in the last quarter. Institutional investors own 76.45% of the company’s stock.

In related news, CFO Geoff Race sold 5,999 shares of the stock in a transaction dated Monday, December 17th. The shares were sold at an average price of $7.46, for a total value of $44,752.54. Following the completion of the transaction, the chief financial officer now directly owns 204,369 shares in the company, valued at approximately $1,524,592.74. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 12,890 shares of company stock valued at $96,159. 9.60% of the stock is owned by company insiders.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Recommended Story: What factors cause inflation to rise?

Earnings History and Estimates for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: International Speedway Corp  Receives Average Rating of “Hold” from Brokerages
Zacks: International Speedway Corp Receives Average Rating of “Hold” from Brokerages
Citigroup Cuts Magna International  Price Target to $62.00
Citigroup Cuts Magna International Price Target to $62.00
Investors Buy Large Volume of Put Options on Sumitomo Mitsui Financial Grp
Investors Buy Large Volume of Put Options on Sumitomo Mitsui Financial Grp
Baytex Energy  Trading Down 6.5%
Baytex Energy Trading Down 6.5%
CorePoint Lodging  Lifted to “Hold” at Zacks Investment Research
CorePoint Lodging Lifted to “Hold” at Zacks Investment Research
Conduent  vs. HMS  Critical Review
Conduent vs. HMS Critical Review


© 2006-2019 Ticker Report